Recruiting × Adenocarcinoma Of Esophagus × 30 days × Clear all A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Phase 1 Recruiting
310 enrolled
Obeticholic Acid for Prevention in Barrett's Esophagus
Phase 2 Recruiting
30 enrolled
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
290 enrolled
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Phase 1/2 Recruiting
768 enrolled
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Phase 2/3 Recruiting
224 enrolled
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 Recruiting
1,006 enrolled
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
330 enrolled
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Phase 3 Recruiting
382 enrolled
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Phase 2/3 Recruiting
690 enrolled
OLIGOMETS
Phase 2 Recruiting
54 enrolled
A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Phase 1 Recruiting
154 enrolled
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
Phase 2 Recruiting
180 enrolled
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
280 enrolled
Endeavor-1
Phase NA Recruiting
50 enrolled
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Phase 3 Recruiting
2,130 enrolled
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Phase 1/2 Recruiting
159 enrolled
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Phase 1 Recruiting
60 enrolled